Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries
GSK has a deep commitment to improving healthcare by developing innovative new medicines and widening access to them around the world.
Read more -
GSK receives marketing authorisation for Nucala® (mepolizumab) in Japan
GSK announces that the Japanese Ministry of Health, Labour and Welfare has granted approval for Nucala® (mepolizumab) as a treatment for bronchial asthma.
Read more -
Sir Andrew Witty to retire from GSK in March 2017
In the publication of its 2015 Annual Report to shareholders, GSK plc today announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the com...
Read more -
GlaxoSmithKline plc (the “Company”) Directorate changes
The Company today announces that Sir Deryck Maughan, Dr Stephanie Burns, Dr Daniel Podolsky and Hans Wijers will not stand for re-election to the Board at GSK’s Annual General M...
Read more -
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma
GSK today announced results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study.
Read more -
GSK and Miltenyi Biotec establish cell and gene therapy collaboration
Collaboration includes discovery programme for CAR-T cell-based oncology therapies
Read more -
GSK presents data at AAAAI on efficacy of Nucala® (mepolizumab) in severe asthma patients stratified by eosinophil levels
GSK today presented results at the American Academy of Allergy, Asthma & Immunology annual meeting from a post-hoc study which showed that severe asthma patients with a baseline...
Read more -
NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma
GSK today announced publication of results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359) in the New England Journal of Medicine.
Read more -
GSK presents new data on the long-term efficacy & safety of Nucala® for the treatment of severe asthma with an eosinophilic phenotype
GSK today presented new safety and efficacy data for Nucala® (mepolizumab) from the open-label COSMOS (MEA115661) study at the American Academy of Allergy, Asthma & Immunology a...
Read more -
GSK names winners of 2015 Discovery Fast Track Challenge
Six winning proposals were selected from 378 entries submitted from 21 countries across Europe and North America
Read more -
New long-term organ damage analysis published for GSK’s Benlysta® (belimumab)
Patients with SLE are at risk of irreversible organ damage which will accrue over time and is associated with increased risk of death1.
Read more -
ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir
Results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
Read more -
ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment
32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen
Read more -
Four inspiring innovations which help reduce child deaths in developing countries share $1 million prize from GSK and Save the Children
Healthcare Innovation Award is a major initiative within five-year partnership to help save one million children’s lives
Read more -
GSK’s global HIV business ViiV Healthcare completes transactions to acquire Bristol-Myers Squibb’s R&D HIV assets
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has completed two previously announced transacti...
Read more -
Results announcement for the fourth quarter 2015
GSK delivers further progress against strategy with 2015 sales of £24 billion (+6%), core EPS 75.7p (-15%) and total EPS 174.3p, +>100% CER 2016 core EPS percentage growth ex...
Read more -
GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+
This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses
Read more -
GSK and Adaptimmune expand strategic immunotherapy collaboration
GSK and Adaptimmune Therapeutics have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer programme
Read more -
Global pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance
Leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, call on governments and industry to work in parallel in ...
Read more -
ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration with Janssen Sciences Ireland UC ...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
